Heart and liver fatty acid binding proteins and the metabolic syndrome

Current Hypertension Reports

Volumn 7, Issue 6, 2005, Pages 401-406

  Binas, Bert ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; CYTOSKELETON PROTEIN; FATTY ACID; FATTY ACID BINDING PROTEIN; LIVER PROTEIN; MUSCLE PROTEIN; PROTEIN INHIBITOR;

ADIPOCYTE; CYTOSOL; FATTY ACID METABOLISM; HEART; LIVER CYTOSOL; METABOLIC SYNDROME X; MOUSE STRAIN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; CYTOSOL; FATTY ACID-BINDING PROTEINS; HUMANS; LIVER; METABOLIC SYNDROME X; MYOCARDIUM; SEVERITY OF ILLNESS INDEX;

EID: 31344455984     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-005-0033-0     Document Type: Review

References (50)

1. Moller DE, Kaufman KD: Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 2005, 56:45-62.
2. Wellen KE, Hotamisligil GS: Inflammation, stress, and diabetes. J Clin Invest 2005, 115:1111-1119.
3. Shulman GI: Cellular mechanisms of insulin resistance. J Clin Invest 2000, 106:171-176.
4. Unger RH: Weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 2003, 144:5159-5165.
5. Hertzel AV, Bernlohr DA: The mammalian fatty acid-binding protein multigene family: molecular and genetic insights into function. Trends Endocrinol Metab 2000, 11:175-180.
6. Storch J, Thumser AE: The fatty acid transport function of fatty acid-binding proteins. Biochim Biophys Acta 2000, 1486:28-44
7. Stewart JM: The cytoplasmic fatty-acid-binding proteins: thirty years and counting. Cell Mol Life Sci 2000, 57:1345-1359.
8. Glatz JF, Storch J: Unravelling the significance of cellular fatty acid-binding proteins. Curr Opin Lipidol 2001, 12:267-274.
9. Boord JB, Fazio S, Linton MF: Cytoplasmic fatty acid-binding proteins: emerging roles in metabolism and atherosclerosis. Curr Opin Lipidol 2002, 13:141-147.
10. Weisiger RA: Cytosolic fatty acid binding proteins catalyze two distinct steps in intracellular transport of their ligands. Mol Cell Biochem 2002, 239:35-43.
11. Makowski L, Brittingham KC, Reynolds JM, et al.: The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities. J Biol Chem 2005, 280:12888-12895.
12. Shen WJ, Sridhar K, Bernlohr DA, Kraemer FB: Interaction of rat hormone-sensitive lipase with adipocyte lipid-binding protein. Proc Natl Acad Sci U S A 1999, 96:5528-5532.
13. Hagens G, Masouye I, Augsburger E, et al.: Calcium-binding protein S100A7 and epidermal-type fatty acid-binding protein are associated in the cytosol of human keratinocytes. Biochem J 1999, 339:419-427.
14. Wolfrum C, Borrmann CM, Borchers T, Spener F: Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha- and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus. Proc Natl Acad Sci U S A 2001, 98:2323-2328.
15. Tan NS, Shaw NS, Vinckenbosch N, et al.: Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription. Mol Cell Biol 2002, 22:5114-5127.
16. Jenkins-Kruchten AE, Bennaars-Eiden A, Ross JR, et al.: Fatty acid-binding protein-hormone-sensitive lipase interaction. Fatty acid dependence on binding. J Biol Chem 2003, 278:47636-47643.
17. Hanhoff T, Lucke C, Spener F: Insights into binding of fatty acids by fatty acid binding proteins. Mol Cell Biochem 2002, 239:45-54.
18. Haunerland NH, Spener F: Fatty acid-binding proteins: insights from genetic manipulations. Prog Lipid Res 2004, 43:328-349.
19. Hotamisligil GS, Johnson RS, Distel RJ, et al.: Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 1996, 274:1377-1379.
20. Uysal KF, Scheja L, Wiesbrock SM, et al.: Improved glucose and lipid metabolism in genetically obese mice lacking aP2. Endocrinology 2000, 141:3388-3396.
21. Makowski L, Boord JB, Maeda K, et al.: Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 2001, 7:699-705.
22. Maeda K, Uysal KF, Makowski L, et al.: Role of the fatty acid binding protein mall in obesity and insulin resistance. Diabetes 2003, 52:300-307.
23. Maeda K, Cao H, Kono K, et al.: Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab 2005, 1:107-119.
24. Coe NR, Simpson MA, Bernlohr DA: Targeted disruption of the adipocyte lipid-binding protein (aP2 protein) gene impairs fat cell lipolysis and increases cellular fatty acid levels. J Lipid Res 1999, 40:967-972.
25. Scheja L, Makowski L, Uysal KT, et al.: Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice. Diabetes 1999, 48:1987-1994.
26. Shaughnessy S, Smith ER, Kodukula S, et al.: Adipocyte metabolism in adipocyte fatty acid binding protein knockout mice (aP2-/-) after short-term high-fat feeding: functional compensation by the keratinocyte fatty add binding protein. Diabetes 2000, 49:904-911.
27. Samuel VT, Liu ZX, Qu X, et al.: Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004, 279:32345-32353.
28. Kershaw EE, Flier JS: Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89:2548-2556.
29. Desvergue B, Michalik L, Wahli W: Be fit or be sick: peroxisome proliferator-activated receptors are down the road. Mol Endocrinol 2004, 18:1321-1332.
30. Kintscher U, Law RE: PPARgamma-mediated insulin sensitization: the importance of fat versus muscle. Am J Physiol Endocrinol Metab 2005, 288:E287-E291.
31. Binas B, Danneberg H, McWhir J, et al.: Requirement for the heart-type fatty acid binding protein in cardiac fatty acid utilization. FASEB J 1999, 13:805-812.
32. Murphy EJ, Barcelo-Coblijn G, Binas B, Glatz JF: Heart fatty acid uptake is decreased in heart fatty acid-binding protein gene-ablated mice. J Biol Chem 2004, 279:34481-34488.
33. Shearer J, Fueger PT, Rottman JN, et al.: Heart-type fatty acid-binding protein reciprocally regulates glucose and fatty acid utilization during exercise. Am J Physiol Endocrinol Metab 2005, 288:E292-E297.
34. Schaap FG, Binas B, Danneberg H, et al.: Impaired long-chain fatty add utilization by cardiac myocytes isolated from mice lacking the heart-type fatty acid binding protein gene. Circ Res 1999, 85:329-337.
35. Erol E, Cline GW, Kim JK, et al.: Nonacute effects of H-FABP deficiency on skeletal muscle glucose uptake in vitro. Am J Physiol Endocrinol Metab 2004, 287:E977-E282.
36. Binas B, Han XX, Erol E, et al.: A null mutation in H-FABP only partially inhibits skeletal muscle fatty add metabolism. Am J Physiol Endocrinol Metab 2003, 285:E481-E489.
37. Shearer J, Fueger PT, Bracy DP, et al.: Reduced muscle-type fatty acid binding protein (FABP) protects against diet-induced insulin resistance. ADA Annual Meeting 2004, Abstract 1401-P.
38. Randle PJ: Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab Rev 1998, 14:263-283.
39. Sugden MC, Bulmer K, Holness MJ: Fuel-sensing mechanisms integrating lipid and carbohydrate utilization. Biochem Soc Rans 2001, 29:272-278.
40. Petersen AM, Pedersen BK: The anti-inflammatory effect of exercise. J Appl Physiol 2005, 98:1154-1162.
41. Newberry EP, Xie Y, Kennedy S, et al.: Decreased hepatic triglyceride accumulation and altered fatty acid uptake in mice with deletion of the liver fatty acid-binding protein gene. J Biol Chem 2003, 278:51664-51672.
42. Erol E, Kumar LS, Cline GW, et al.: Liver fatty acid binding protein is required for high rates of hepatic fatty acid oxidation but not for the action of PPARalpha in fasting mice. FASEB J 2004, 18:347-349.
43. Lam TK, Carpentier A, Lewis GF, et al.: Mechanisms of the free fatty acid-induced increase in hepatic glucose production. Am J Physiol Endocrinol Metab 2003, 284:E863-E873.
44. Lee SS, Pineau T, Drago J, et al.: Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 1995, 15:3012-3022.
45. Brouillette C, Bosse Y, Perusse L, et al.: Effect of liver fatty acid binding protein (FABP) T94A missense mutation on plasma lipoprotein responsiveness to treatment with fenofibrate. J Hum Genet 2004, 49:424-432.
46. Zammit VA: Insulin stimulation of hepatic triacylglycerol secretion in the insulin-replete state: implications for the etiology of peripheral insulin resistance. Ann N Y Acad Sci 2002, 967:52-65.
47. Hajri T, Han XX, Bonen A, Abumrad NA: Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in CD36-null mice. J Clin Invest 2002, 109:1381-1389.
48. Baar RA, Dingfelder CS, Smith LA, et al.: Investigation of in vivo fatty add metabolism in AFABP/aP2(-/-) mice. Am J Physiol Endocrinol Metab 2005, 288:E187-E193.
49. Semenkovich CF: Fatty acid metabolism and vascular disease. Trends Cardiovasc Med 2004, 14:72-76.
50. Basciano H, Federico L, Adeli K: Fructose, insulin resistance, and metabolic dyslipidemia. Nutr Metab (Lond) 2005, 21, 2:5.